97 related articles for article (PubMed ID: 12824949)
1. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates.
Gallego O; Corral A; De Mendoza C; Gonzalez-Lahoz J; Soriano V
Med Sci Monit; 2003 Jun; 9(6):CR217-21. PubMed ID: 12824949
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of primary and secondary resistant mutations to antiretroviral drug in a population of Puerto Rican infected with HIV.
Torres Rivera B; Vallés V; Ríos Olivares E
P R Health Sci J; 2002 Dec; 21(4):329-36. PubMed ID: 12572241
[TBL] [Abstract][Full Text] [Related]
3. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
4. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
[TBL] [Abstract][Full Text] [Related]
6. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
7. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
8. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
[TBL] [Abstract][Full Text] [Related]
9. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
[TBL] [Abstract][Full Text] [Related]
10. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].
Si XF; Huang HL; Wei M; Guan Q; Song YH; Ma PF; Quan Y; Xing H; Shao YM
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):308-11. PubMed ID: 15650776
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
[TBL] [Abstract][Full Text] [Related]
13. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
14. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
[TBL] [Abstract][Full Text] [Related]
15. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
17. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
18. [Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)].
Acevedo W; Gallardo AM; Galaz J; Afani A; Cortés E
Rev Med Chil; 2007 Nov; 135(11):1406-13. PubMed ID: 18259651
[TBL] [Abstract][Full Text] [Related]
19. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
Novak RM; Chen L; MacArthur RD; Baxter JD; Huppler Hullsiek K; Peng G; Xiang Y; Henely C; Schmetter B; Uy J; van den Berg-Wolf M; Kozal M;
Clin Infect Dis; 2005 Feb; 40(3):468-74. PubMed ID: 15668873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
